Felbinac: Uses, Dosage, Side Effects and More

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Topical/Cutaneous
Pain and inflammation

Adult: For the symptomatic relief of rheumatic pain, pain of non-serious arthritic conditions and soft tissue injuries (including strains, sprains, and contusions): As 3% gel: Apply approx 1 inch (approx 1 g) into the affected area(s) 2-4 times daily. Max: 25 g daily (regardless of the size or number of affected areas). Reassess treatment after 14 days.

Contraindications

Hypersensitivity to felbinac, aspirin, or other NSAIDs (including history of urticaria, acute rhinitis, or asthma precipitated by aspirin or other NSAIDs).

Special Precautions

Patient with other types of asthma. Application in large amounts. Pregnancy and lactation.

Adverse Reactions

Significant: Anaphylactoid reactions; skin photosensitivity; rash; systemic effects (e.g. asthma, hypersensitivity and renal disease), particularly when applied in large amounts.
Gastrointestinal disorders: Rarely, gastrointestinal disturbances.
Nervous system disorders: Paraesthesia.
Respiratory, thoracic and mediastinal disorders: Bronchospasm, dyspnoea, wheezing.
Skin and subcutaneous tissue disorders: Mild erythema, pruritus, irritation, dermatitis; bullous dermatoses (e.g. epidermal necrolysis, erythema multiforme).

Patient Counseling Information

Avoid excessive sunlight exposure to treated areas. Do not apply to open wounds or diseased skin. Avoid contact with the eyes or mucous membranes. Do not use occlusive dressings unless directed by the doctor.

Drug Interactions

May increase the incidence of adverse effects when concomitantly used with aspirin or other NSAIDs.

Action

Description:
Mechanism of Action: Felbinac is a non-steroidal anti-inflammatory drug (NSAID) that has analgesic and anti-inflammatory properties. It reversibly inhibits the cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, thereby reducing inflammation.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 12-24 hours.
Distribution: Preferentially distributed to the site of inflammation.

Chemical Structure

Storage

Store at or below 25°C. Use within 1 month after opening.

MIMS Class

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

ATC Classification

M02AA08 - felbinac ; Belongs to the class of non-steroidal antiinflammatory preparations for topical use. Used in the treatment of joint and muscular pains.

References

Brayfield A, Cadart C (eds). Felbinac. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2024.

Felbinac. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 05/11/2024.

Joint Formulary Committee. Felbinac. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2024.

Traxam 3% w/w Gel (Mercury Pharmaceuticals Ltd). MHRA. https://products.mhra.gov.uk. Accessed 05/11/2024.

Disclaimer: This information is independently developed by MIMS based on Felbinac from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com